Loading clinical trials...
Loading clinical trials...
Safety and Efficacy of Pyrotinib Combined With Thalidomide in Advanced Non-Small-Cell Lung Cancer With HER2 Exon 20 Insertions: A Prospective, Single-arm, Open-label Phase II Study
Conditions
Interventions
pyrotinib combined with thalidomide
Locations
1
China
Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University
Shanghai, China
Start Date
June 30, 2020
Primary Completion Date
October 1, 2022
Completion Date
April 1, 2023
Last Updated
January 28, 2021
NCT07336732
NCT05568212
NCT06574347
NCT02448992
NCT06281964
NCT05904379
Lead Sponsor
Shanghai Chest Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions